Még nem toboroz
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Még nem toboroz
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
NCT07857486· 2. fázis· Institut Paoli-Calmettes· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.
2025-521437-88-00· 2. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Toboroz
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· 3. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NCT07436312· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Contact: Bruno Raynard, MD
Toboroz
Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
NCT07043543· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás
Contact: Nathalie ROUARD, MD
Toboroz
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Toboroz
Early detection of triple negative breast cancer relapse (CUPCAKE)
2022-501562-22-01· 2. fázis· Institut Curie· Forrás
Toboroz
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· 3. fázis· Zai Lab (Shanghai) Co., Ltd.· Forrás
Toboroz
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
NCT06959108· 2. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07028125· 4. fázis· Centre Francois Baclesse· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
2023-503326-39-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725· 2. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· 3. fázis· OSE Immunotherapeutics· Forrás
Contact: Caroline Chevalier, MSc, MPH
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
NCT06557889· 2. fázis· Institut Claudius Regaud· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients with Breast Cancer
NCT06112379· 3. fázis· Astrazeneca AB· Forrás
Toboroz
CARE1 Pragmatic Clinical Trial
NCT06364631· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Contact: Bertrand BILLEMONT, MD
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)
NCT06924099· NovoCure Ltd.· Forrás
Contact: inst INSTITUT SAINTE-CATHERINE
Toboroz
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC)
2022-500743-20-00· 2. fázis· Institut Curie· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· 2. fázis· UNICANCER· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Toboroz
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
NCT05346848· 2. fázis· Institut Bergonié· Forrás
Fut, nem toboroz
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study
NCT05909111· Recherche clinique· Forrás
Contact: Antoine Arnaud, DM
Fut, nem toboroz
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
NCT05201352· 1/2. fázis· Centre Georges Francois Leclerc· Forrás
Toboroz
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
NCT05116475· 3. fázis· Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Toboroz
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04747054· 3. fázis· UNICANCER· Forrás
Contact: Benoit CALDERON, Dr (principal investigator)
Fut, nem toboroz
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation
NCT04964934· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
NCT04823377· Institut Curie· Forrás
Fut, nem toboroz
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer
NCT04784714· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565· 3. fázis· GBG Forschungs GmbH· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
NCT04115007· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
NCT03870919· UNICANCER· Forrás
Showing 50 of 65.